Drug Trial Radar · NCT07940803
A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 13, 2026
Primary completion
Mar 25, 2028
Study completion Mar 25, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn more about NNC0662-3168 as a potential treatment for people living with overweight or obesity and/or type 2 diabetes(T2D). The study will investigate its safety, tolerability and its effects in the body. The study will be conducted in four parts. Part A: Single Ascending Dose, Part B: Multiple Ascending Dose: Part C: Dose-finding in Weight Management. Part D: T2D proof-of-concept.
Conditions
- Overweight
- Obesity
- Type 2 Diabetes Mellitus
Interventions
NNC0662-3168 (Test product-A)Drug
NNC0662-3168 is administered subcutaneously.
Placebo matched to NNC0662-3168 (Test product-A)Drug
Placebo is administered subcutaneously.
Active Comparator (Product-B)Drug
Active Comparator is administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of treatment-emergent adverse events (TEAEs)Time frame: From dosing on day 1 upto 29 days
- Part B: Number of treatment-emergent adverse events (TEAEs)Time frame: From dosing at week 0 up to 39 weeks
- Part C: Change in body weightTime frame: From baseline (week 0) to week 36
- Part D: Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to week 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Celerion, Phoenix
Tempe, Arizona
Celerion, Lincoln
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.